NCT07023055

Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

Multicenter Prospective Cohort Study on TAM Receptor Tyrosine Kinase Ligands for Predicting the Severity of Acute Pancreatitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 896 (actual)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.

Conditions

• Acute Pancreatic Necrosis
• Acute Pancreatitis (AP)

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-03-01
• Completion: 2025-03-01
• First posted: 2025-06-15
• Last updated: 2025-06-22

Locations

1 site across 1 country: China